161 related articles for article (PubMed ID: 8985519)
21. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
22. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
[TBL] [Abstract][Full Text] [Related]
23. Calculating regional tissue volume for hyperthermic isolated limb perfusion: Four methods compared.
Cecchin D; Negri A; Frigo AC; Bui F; Zucchetta P; Bodanza V; Gregianin M; Campana LG; Rossi CR; Rastrelli M
Eur J Surg Oncol; 2016 Dec; 42(12):1898-1905. PubMed ID: 27005884
[TBL] [Abstract][Full Text] [Related]
24. Hyperthermic isolated limb perfusion. The switch from Steinmann pins to Omni-tract assisted isolation.
Stamatiou D; Ioannou CV; Kontopodis N; Michelakis D; Perisinakis K; Lasithiotakis K; Zoras O
J Surg Res; 2017 Jun; 213():147-157. PubMed ID: 28601307
[TBL] [Abstract][Full Text] [Related]
25. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas.
Deroose JP; Eggermont AM; van Geel AN; Burger JW; den Bakker MA; de Wilt JH; Verhoef C
J Clin Oncol; 2011 Oct; 29(30):4036-44. PubMed ID: 21931039
[TBL] [Abstract][Full Text] [Related]
26. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation.
Gutman M; Inbar M; Lev-Shlush D; Abu-Abid S; Mozes M; Chaitchik S; Meller I; Klausner JM
Cancer; 1997 Mar; 79(6):1129-37. PubMed ID: 9070490
[TBL] [Abstract][Full Text] [Related]
27. Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: the value of adjuvant radiotherapy.
Thijssens KM; van Ginkel RJ; Pras E; Suurmeijer AJ; Hoekstra HJ
Ann Surg Oncol; 2006 Apr; 13(4):518-24. PubMed ID: 16485147
[TBL] [Abstract][Full Text] [Related]
28. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.
Lienard D; Ewalenko P; Delmotte JJ; Renard N; Lejeune FJ
J Clin Oncol; 1992 Jan; 10(1):52-60. PubMed ID: 1727926
[TBL] [Abstract][Full Text] [Related]
29. Multifocal soft tissue sarcoma: limb salvage following hyperthermic isolated limb perfusion with high-dose tumor necrosis factor and melphalan.
Lev-Chelouche D; Abu-Abeid S; Kollander Y; Meller I; Isakov J; Merimsky O; Klausner JM; Gutman M
J Surg Oncol; 1999 Mar; 70(3):185-9. PubMed ID: 10102350
[TBL] [Abstract][Full Text] [Related]
30. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
J Clin Oncol; 1996 Feb; 14(2):479-89. PubMed ID: 8636761
[TBL] [Abstract][Full Text] [Related]
31. [Tumor necrosis factor α and melfalan-based hyperthermic isolated limb perfusion in locally advanced extremity soft tissue sarcomas and melanomas].
Alegre JF; Duarte M; Sureda González M; Bretcha Boix P; Dussan C; Ballester A; Crespo A; Brugarolas Masllorens A
Cir Esp; 2012 Feb; 90(2):114-20. PubMed ID: 22225611
[TBL] [Abstract][Full Text] [Related]
32. Hyperthermic isolated perfusion with low-dose tumor necrosis factor alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcomas.
Rossi CR; Mocellin S; Pilati P; Foletto M; Campana L; Quintieri L; De Salvo GL; Lise M
Ann Surg Oncol; 2005 May; 12(5):398-405. PubMed ID: 15915374
[TBL] [Abstract][Full Text] [Related]
33. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial.
Eggermont AM; Schraffordt Koops H; Liénard D; Kroon BB; van Geel AN; Hoekstra HJ; Lejeune FJ
J Clin Oncol; 1996 Oct; 14(10):2653-65. PubMed ID: 8874324
[TBL] [Abstract][Full Text] [Related]
34. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
[TBL] [Abstract][Full Text] [Related]
35. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion with melphalan and high-dose tumor necrosis factor.
Fraker DL; Alexander HR; Andrich M; Rosenberg SA
Cancer J Sci Am; 1995; 1(2):122-30. PubMed ID: 9166465
[TBL] [Abstract][Full Text] [Related]
36. High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan.
Zwaveling JH; Maring JK; Clarke FL; van Ginkel RJ; Limburg PC; Hoekstra HJ; Koops HS; Girbes AR
Crit Care Med; 1996 May; 24(5):765-70. PubMed ID: 8706451
[TBL] [Abstract][Full Text] [Related]
37. Quality of life after hyperthermic isolated limb perfusion for locally advanced extremity soft tissue sarcoma.
Thijssens KM; Hoekstra-Weebers JE; van Ginkel RJ; Hoekstra HJ
Ann Surg Oncol; 2006 Jun; 13(6):864-71. PubMed ID: 16614886
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant Hypertermic Isolated Limb Perfusion in Treatment of Undifferentiated Spindle Cell Sarcoma of Lower Limb with Achieved Complete Pathologic Response.
Vočka M; Špaček M; Matějovský Z; Trnka J; Hodková G; Skibová D; Zogala D; Lindner J; Petruželka L
Klin Onkol; 2019; 32(3):211-213. PubMed ID: 31216854
[TBL] [Abstract][Full Text] [Related]
39. [Regional chemotherapy--perfusion of the extremities].
Meyer T; Göhl J
Kongressbd Dtsch Ges Chir Kongr; 2001; 118():200-4. PubMed ID: 11824246
[TBL] [Abstract][Full Text] [Related]
40. Impact of hyperthermic isolated limb perfusion on tumour oxygenation in soft tissue sarcoma.
Jakob J; von Rege I; Weiss C; Hohenberger P
Int J Hyperthermia; 2012; 28(7):591-6. PubMed ID: 22946472
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
